Vonicog alfa

Drug Profile

Vonicog alfa

Alternative Names: BAX 111; Recombinant von Willebrand factor; rVWF; VEYVONDI; Vonvendi

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Max Delbruck Center for Molecular Medicine
  • Developer Shire
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Proteins; Recombinant proteins
  • Mechanism of Action Factor VIII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Willebrand disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Von Willebrand disease

Most Recent Events

  • 22 Jun 2017 The EMA validates the MAA for Vonicog alfa for the treatment of Von Willebrand's disease in European Union
  • 14 Feb 2017 Phase-III clinical trials in Von Willebrand's disease (Prevention) in Spain (IV) (EudraCT2016-001478-14)
  • 02 Dec 2016 Shire announces intention to submit expansion to marketing approval to EMA and USFDA in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top